Skip to content
lsd.com

Louisiana

Psychedelic trials in Louisiana

14 registered trials has a study site in Louisiana, and 2 are recruiting now.

14
Trials with a site here
2
Recruiting
10
Facilities

Open now

Recruiting in this state

TrialStatusPhaseSubstanceSites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL LimitedRecruitingPhase 3psilocybin68
Psilocybin for Methamphetamine AddictionNCT06899594 · Kevin MurnaneRecruitingEarly Phase 1psilocybin1

Facilities

Where the research happens in Louisiana

FacilityCityTrials
Ray Worthy Psychiatry LLCNew Orleans4
Lake Charles Clinical TrialsLake Charles2
Tandem Clinical ResearchMarrero1
Atlas PsychiatryNew Orleans1
LSU Health ShreveportShreveport1
DelRicht ResearchNew Orleans1
Ray Worthy PsychiatryNew Orleans1
LSU Health Sciences Center New OrleansNew Orleans1
Louisiana Clinical ResearchShreveport1
Biomedical Research Foundation of Northwest LouisianaShreveport1

Stay told

When a trial opens in Louisiana

Research alerts

Get a notification when a trial for trials in Louisiana starts recruiting

This registry is rebuilt every day. If no trial is recruiting for you today, that can change within weeks.

This form sends your email address and the topic of this page to Brevo, our email provider, which stores them on servers in the European Union. We never sell that address, never share it with anyone, and never use it for advertising. One email deletes it. What is held, and where.

All trials

Every trial with a Louisiana site

TrialStatusPhaseSubstanceSites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL LimitedRecruitingPhase 3psilocybin68
Psilocybin for Methamphetamine AddictionNCT06899594 · Kevin MurnaneRecruitingEarly Phase 1psilocybin1
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · Cybin IRL LimitedActive, not recruitingPhase 3psilocybin45
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)NCT03537014 · Resilient PharmaceuticalsCompletedPhase 3mdma15
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)NCT04077437 · Resilient PharmaceuticalsCompletedPhase 3mdma14
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSDNCT04714359 · Resilient PharmaceuticalsCompletedPhase 3mdma15
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLCCompletedPhase 3ketamine155
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLCCompletedPhase 3ketamine173
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192 · Janssen Research & Development, LLCCompletedPhase 3ketamine56
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · Janssen Research & Development, LLCCompletedPhase 3ketamine61
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT03434041 · Janssen Research & Development, LLCCompletedPhase 3ketamine30
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSDNCT03282123 · Resilient PharmaceuticalsCompletedPhase 2mdma12
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · Janssen Research & Development, LLCCompletedPhase 2ketamine51
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionNCT03775200 · COMPASS PathwaysCompletedPhase 2psilocybin25

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere

Other states